Company Filing History:
Years Active: 2022-2025
Title: Michael Cannarile: Innovator in Cancer Treatment
Introduction
Michael Cannarile is a notable inventor based in Penzberg, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and development efforts. His work focuses on combination therapies that enhance the effectiveness of existing treatments.
Latest Patents
Cannarile holds a patent for a groundbreaking invention titled "Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment." This invention relates to a combination therapy that utilizes an anti-CSF-1R antibody, particularly a CSF-1R dimerization inhibitor, alongside an anti-PD-L1 antibody. This therapy is designed for patients who have experienced treatment failure with PD1/PD-L1 inhibitors, offering a new avenue for effective cancer treatment.
Career Highlights
Michael Cannarile is currently employed at Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work at this esteemed organization has allowed him to collaborate with other talented professionals in the field.
Collaborations
Cannarile has worked alongside notable colleagues such as Anna-Maria Jegg and Francesca Michielin. Their combined expertise contributes to the advancement of innovative cancer therapies.
Conclusion
Michael Cannarile's contributions to cancer treatment through his patented combination therapy highlight his role as a significant innovator in the medical field. His work continues to pave the way for new treatment options for patients facing challenging diagnoses.